In the preceding three months, 9 analysts have released ratings for 10x Genomics TXG, presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 1 | 4 | 0 | 1 |
| Last 30D | 0 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 2 | 0 | 3 | 0 | 1 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $39.0, along with a high estimate of $55.00 and a low estimate of $24.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 26.94%.
Interpreting Analyst Ratings: A Closer Look
The analysis of recent analyst actions sheds light on the perception of 10x Genomics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tycho Peterson | Jefferies | Announces | Hold | $24.00 | - |
| Dan Leonard | UBS | Lowers | Neutral | $30.00 | $52.00 |
| Derik De Bruin | B of A Securities | Lowers | Neutral | $36.00 | $45.00 |
| Matthew Sykes | Goldman Sachs | Lowers | Sell | $26.00 | $30.00 |
| Dan Brennan | TD Cowen | Lowers | Hold | $32.00 | $57.00 |
| Daniel Arias | Stifel | Lowers | Buy | $53.00 | $63.00 |
| Kyle Mikson | Canaccord Genuity | Lowers | Buy | $50.00 | $65.00 |
| Justin Bowers | Deutsche Bank | Lowers | Buy | $55.00 | $60.00 |
| Luke Sergott | Barclays | Lowers | Overweight | $45.00 | $55.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to 10x Genomics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of 10x Genomics compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for 10x Genomics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of 10x Genomics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on 10x Genomics analyst ratings.
Discovering 10x Genomics: A Closer Look
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Financial Milestones: 10x Genomics's Journey
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: 10x Genomics's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 5.0%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: 10x Genomics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -42.52%, the company may face hurdles in effective cost management.
Return on Equity (ROE): 10x Genomics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -8.21%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): 10x Genomics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -6.35%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: 10x Genomics's debt-to-equity ratio is below the industry average. With a ratio of 0.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
The Significance of Analyst Ratings Explained
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
